Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trialJürgen C. Becker, Lucie Heinzerling, Selma Ugurel et al.|The Lancet|2023Cited by 75
Improved survival of advanced melanoma patients receiving immunotherapy with concomitant antithrombotic therapy – A multicenter study on 2419 patients from the prospective skin cancer registry ADORegJulian Kött, N. Devereux, Tim Zell et al.|European Journal of Cancer|2024Cited by 16
Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patientsAlexander Scheiter, Kirsten Utpatel, Tom Schneider et al.|BMC Medicine|2026Cited by 2
Additional file 1 of Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patientsAlexander Scheiter, Kirsten Utpatel, Simon Mellin et al.|Open MIND|2026Cited by 0
Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patientsAlexander Scheiter, Kirsten Utpatel, Simon Mellin et al.|Figshare|2026Cited by 0